Most Read Articles
4 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 2 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Dupilumab effective for chronic nodular prurigo

20 Jun 2020

Dupilumab is effective for reducing itch and improving skin lesions in patients with chronic nodular prurigo (CNPG), a new study has found.

Researchers conducted a retrospective multicentre analysis of 27 adult CNPG patients (mean age, 52.0±14.9 years; 16 women) who received 16 weeks of dupilumab treatment. Outcome measures included the numerical rating scale (NRS) for itch and sleeplessness, and the Investigator Global Assessment Scale (IGA).

Almost half of the participants had had a personal history of atopic dermatitis (AD) or other AD manifestations, and patients had had CNPG for an average of 13.7±13.6 years. All participants had previously been treated with at least one systemic treatment, and thirteen had failed at least three systemic treatments before dupilumab.

After 4 weeks of treatment, more than half of the patients showed a reduction in IGA score of at least two grades, and there were significant drops in itch and sleeplessness NRS scores (p<0.001). On the other hand, four patients dropped out at this point due to lack of efficacy or worsening CNPG.

Of the 23 remaining patients by week 16, 47.8 percent (n=11) were deemed to have very mild disease by IGA, while 21.7 percent (n=5) had mild disease. Nineteen participants (82.6 percent) achieved an 2-grade decrease in IGA.

Relative to baseline, itch NRS dropped from 8.9 to 2.7, while sleeplessness NRS decreased from 8.2 to 1.7 (p<0.001 for both). Ten patients were able to reach 36 weeks of treatment with sustained clinical efficacy.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 2 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.